The cardiology positron emission tomography (PET) scan market is witnessing steady growth due to increasing demand for accurate, non-invasive cardiac imaging solutions. PET scans offer superior diagnostic capabilities in detecting coronary artery disease, assessing myocardial viability, and guiding treatment plans. Growing prevalence of cardiovascular disorders, rising geriatric population, and technological advancements in imaging systems—such as hybrid PET/CT and PET/MRI—are key factors propelling market expansion. North America currently leads the market due to well-established healthcare infrastructure and early adoption of advanced diagnostic technologies, while Asia Pacific is emerging rapidly driven by healthcare investments and growing awareness. However, challenges like high equipment costs and limited access to radiopharmaceuticals in certain regions may restrain growth.
According to Fortune Business Insights, the global cardiology positron emission tomography (PET) scan market size was valued at USD 1.91 billion in 2024. The market is projected to grow from USD 1.97 billion in 2025 to USD 2.56 billion by 2032, exhibiting a CAGR of 3.8% during the forecast period. North America dominated the cardiology positron emission tomography scan market with a market share of 55.49% in 2024.
In April 2025, Southcoast Health (U.S.) announced the launch of new imaging suites offering advanced PET/CT scans for neurology, oncology, and cardiology at their facilities. This reflects growing demand for integrated imaging services leveraging combined anatomical and metabolic data with greater diagnostic precision.